| Literature DB >> 24040159 |
Meng-Yun Wang1, Mei-Ling Zhu, Jing He, Ting-Yan Shi, Qiao-Xin Li, Ya-Nong Wang, Jin Li, Xiao-Yan Zhou, Meng-Hong Sun, Xiao-Feng Wang, Ya-Jun Yang, Jiu-Cun Wang, Li Jin, Qing-Yi Wei.
Abstract
BACKGROUND: Caspase 7 (CASP7) is an important regulator and executioner in the apoptosis pathway and plays a crucial role in cancer development and progression. However, few studies have evaluated associations between functional single nucleotide polymorphisms (SNPs) in the 3' untranslational region (UTR) of CASP7 and risk of gastric cancer.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24040159 PMCID: PMC3769357 DOI: 10.1371/journal.pone.0074041
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Gene map and linkage disequilibrium (LD) blocks of the CASP7 gene.
(A) Gene map and potentially functional polymorphisms in the CASP7 gene predicted by SNPinfo. Exons are marked by black blocks, and 3′-UTRs by white blocks. SNPs studied in the present study were in bold. (B) Pairwise linkage disequilibrium (LD) among four selected SNPs of CASP7. The value within each diamond represents the pairwise correlation between SNPs (measured as r2) defined by the upper left and the upper right sides of the diamond. The red-to-white gradient reflects higher to lower LD values.
Frequency distributions of selected characteristics of gastric cancer cases and cancer-free controls.
| Variables | Cases No. (%) | Controls No. (%) | P | |
| All subjects | 1,117 (100.0) | 1,146 (100.0) | ||
| Age, yr | 0.321 | |||
| Range | 21–86 | 22–86 | ||
| Mean | 58.6±11.38 | 59.3±11.30 | ||
| Age group | ||||
| ≤50 | 234 (20.4) | 233 (20.9) | ||
| 51–60 | 375 (32.7) | 380 (34.0) | ||
| 61–70 | 370 (32.3) | 335 (30.0) | ||
| >70 | 167 (14.6) | 169 (15.1) | ||
| Sex | 0.479 | |||
| Males | 793 (71.0) | 798 (69.6) | ||
| Females | 324 (29.0) | 348 (30.4) | ||
| Drinking status | 0.015 | |||
| Ever | 267 (23.9) | 327 (28.5) | ||
| Never | 850 (76.1) | 819 (71.5) | ||
| Smoking status | <0.0001 | |||
| Ever | 433 (38.8) | 570 (49.7) | ||
| Never | 684 (61.2) | 576 (50.3) | ||
| Pack-years | <0.0001 | |||
| 0 | 684 (61.2) | 576 (50.3) | ||
| ≤25 (mean) | 225 (20.1) | 338 (29.5) | ||
| >25 (mean) | 208 (18.6) | 232 (20.2) | ||
| Tumor site | ||||
| GCA | 303 (27.1) | – | ||
| NGCA | 814 (72.9) | – | ||
GCA, gastric cardia adenocarcinoma; NGCA, non-gastric cardia adenocarcinoma.
Two-sided χ2 test for distributions between cases and controls.
Data were presented as mean ± SD.
Logistic regression analysis of associations between the genotypes of CASP7 and gastric cancer risk.
| Variants | Genotypes | Cases (N = 1,117) | Controls (N = 1,146) |
| Crude OR (95% CI) |
| Adjusted OR (95% CI) |
| |
| rs10787498 | |||||||||
| TT | 727 (65.1) | 734 (64.1) | 0.286 | 1.00 | 1.00 | ||||
| GT | 347 (31.1) | 352 (30.7) | 1.00 (0.83–1.19) | 0.959 | 1.00 (0.83–1.19) | 0.960 | |||
| GG | 43 (3.9) | 60 (5.2) | 0.72 (0.48–1.09) | 0.117 | 0.74 (0.50–1.12) | 0.154 | |||
| TT/GT | 1074 (96.2) | 1086 (94.8) | 1.00 | 1.00 | |||||
| GG | 43 (3.9) | 60 (5.2) | 0.114 | 0.73 (0.49–1.08) | 0.115 | 0.75 (0.50–1.12) | 0.152 | ||
| rs1127687 | |||||||||
| GG | 684 (61.2) | 702 (61.3) | 0.769 | 1.00 | 1.00 | ||||
| AG | 376 (33.7) | 378 (33.0) | 1.02 (0.86–1.22) | 0.819 | 1.02 (0.85–1.21) | 0.862 | |||
| AA | 57 (5.1) | 66 (5.8) | 0.89 (0.61–1.28) | 0.523 | 0.90 (0.62–1.30) | 0.575 | |||
| GG/AG | 1060 (94.9) | 1080 (94.2) | 1.00 | 1.00 | |||||
| AA | 57 (5.1) | 66 (5.8) | 0.491 | 0.88 (0.61–1.27) | 0.492 | 0.89 (0.62–1.29) | 0.550 | ||
| rs12247479 | |||||||||
| GG | 885 (79.2) | 889 (77.6) | 0.615 | 1.00 | 1.00 | ||||
| AG | 210 (18.8) | 231 (20.2) | 0.91 (0.74–1.13) | 0.394 | 0.91 (0.74–1.12) | 0.380 | |||
| AA | 22 (2.0) | 26 (2.3) | 0.85 (0.48–1.51) | 0.581 | 0.86 (0.48–1.53) | 0.601 | |||
| GG/AG | 1095 (98.0) | 1120 (97.7) | 1.00 | 1.00 | |||||
| AA | 22 (2.0) | 26 (2.3) | 0.621 | 0.87 (0.49–1.54) | 0.623 | 0.87 (0.49–1.55) | 0.645 | ||
| rs4353229 | |||||||||
| CC | 197 (17.6) | 189 (16.5) | 0.074 | 1.00 | 1.00 | ||||
| CT | 535 (47.9) | 509 (44.4) | 1.01 (0.80–1.27) | 0.944 | 1.00 (0.79–1.27) | 0.978 | |||
| TT | 385 (34.5) | 448 (39.1) | 0.83 (0.65–1.05) | 0.118 | 0.83 (0.65–1.06) | 0.135 | |||
| CC/CT | 732 (65.5) | 698 (60.9) | 1.00 | 1.00 | |||||
| TT | 385 (34.5) | 448 (39.1) |
|
|
|
|
| ||
| Combined effect of risk genotypes | |||||||||
| 0 | 732 (65.5) | 692 (60.4) |
| 1.00 | 1.00 | ||||
| ≥1 | 385 (34.5) | 454 (39.6) |
|
|
|
| |||
CI, confidence interval; OR, odds ratio.
Chi square test for genotype distributions between cases and controls.
Adjusted for age, sex, smoking and drinking status in logistic regress models.
For additive genetic models;
for recessive genetic models. The results were in bold, if the 95% CI excluded 1 or P<0.05.
Stratification analysis for associations between variant genotypes and gastric cancer risk.
| Variables | rs4353229 | Combined risk genotypes | ||||||||||||
| (cases/controls) | Crude OR (95% CI) |
| Adjusted OR(95% CI) |
|
| (cases/controls) | Crude OR(95% CI) |
| Adjusted OR |
|
| |||
| CT/CC | TT | 0 | ≥1 | |||||||||||
| Age | ||||||||||||||
| ≤59 | 387/347 | 188/219 |
|
|
|
| 0.462 | 387/343 | 188/223 |
|
|
|
| 0.410 |
| >59 | 345/351 | 197/229 | 0.88 (0.69–1.12) | 0.280 | 0.90 (0.70–1.15) | 0.391 | 345/349 | 197/231 | 0.86 (0.68–1.10) | 0.219 | 0.89 (0.70–1.14) | 0.345 | ||
| Sex | ||||||||||||||
| Females | 214/206 | 110/142 | 0.75 (0.55–1.02) | 0.067 | 0.75 (0.55–1.03) | 0.072 | 0.480 | 214/203 | 110/145 |
|
|
|
| 0.417 |
| Males | 518/492 | 275/306 | 0.85 (0.70–1.05) | 0.129 | 0.86 (0.70–1.06) | 0.158 | 518/489 | 275/309 | 0.84 (0.69–1.03) | 0.095 | 0.85 (0.69–1.04) | 0.120 | ||
| Smoking status | ||||||||||||||
| Never | 457/350 | 227/226 |
|
|
|
| 0.372 | 457/348 | 227/228 |
|
|
|
| 0.418 |
| Ever | 275/348 | 158/222 | 0.90 (0.70–1.17) | 0.427 | 0.90 (0.70–1.17) | 0.443 | 275/344 | 158/226 | 0.88 (0.98–1.13) | 0.308 | 0.88 (0.68–1.14) | 0.327 | ||
| Drinking status | ||||||||||||||
| Never | 563/500 | 287/319 |
|
|
|
| 0.586 | 563/496 | 287/323 |
|
|
|
| 0.604 |
| Ever | 169/198 | 98/129 | 0.89 (0.64–1.24) | 0.493 | 0.89 (0.64–1.24) | 0.489 | 169/196 | 98/131 | 0.87 (0.62–1.21) | 0.403 | 0.87 (0.62–1.21) | 0.398 | ||
| Site | ||||||||||||||
| Cardia | 194/698 | 109/448 | 0.88 (0.67–1.14) | 0.321 | 0.88 (0.68–1.15) | 0.361 | 0.581 | 194/692 | 109/454 | 0.86 (0.66–1.11) | 0.248 | 0.87 (0.67–1.13) | 0.300 | 0.581 |
| Non–cardia | 538/698 | 276/448 |
|
|
|
| 538/692 | 276/454 |
|
|
|
| ||
CI, confidence interval; OR, odds ratio.
Obtained in logistic regression models with adjustment for age, sex, smoking status and drinking status. P hom derived from the homogeneity test. The results were in bold, if the 95% CI excluded 1 or P<0.05.
MDR analysis for the risk of gastric cancer prediction with and without CASP7 genotypes.
| Best interaction models | Cross-validation | Average prediction error |
|
| 1 | 100/100 | 44.6% | <.0001 |
| 1,2 | 84/100 | 44.4% | <.0001 |
| 1,3,4 | 87/100 | 43.4% | <.0001 |
| 1,3,4,5 | 96/100 | 43.2% | <.0001 |
| 1,3,4,5,6 | 100/100 | 42.6% | <.0001 |
| 1,3,4,5,6,7 | 96/100 | 42.3% | <.0001 |
| 1,2,3,4,5,6,8 | 99/100 | 41.9% | <.0001 |
|
|
|
|
|
MDR, multifactor dimensionality reduction.
P value for 1000-fold permutation test. The best model with maximum cross-validation consistency and minimum prediction error rate was in bold. Labels: 1, smoking status; 2, rs12247479; 3, sex; 4, rs4353229; 5, age; 6, drink status; 7, rs1127687; 8,#rs10787498.
Haplotype analysis for genotypes of CASP7 and Gastric Cancer risk.
| Haplotypes | Haplotype frequencies | Crude OR (95% CI) |
| Adjusted OR(95% CI) |
| |||
| Cases | Controls | |||||||
| n | % | n | % | |||||
| T-G-G-C | 927 | 41.6 | 867 | 37.9 | 1.00 | 1.00 | ||
| T-A-G-T | 488 | 21.9 | 490 | 21.4 | 0.97 (0.83–1.13) | 0.712 | 0.98 (0.83–1.14) | 0.751 |
| T-G-G-T | 384 | 17.2 | 432 | 18.9 | 0.88 (0.74–1.02) | 0.090 | 0.87 (0.74–1.03) | 0.110 |
| G-G-A-T | 254 | 11.4 | 264 | 11.6 | 0.94 (0.77–1.14) | 0.522 | 0.94 (0.78–1.15) | 0.556 |
Obtained in logistic regression models with adjustment for age, sex, smoking status and drinking status.
False-positive report probability values for associations between risk of gastric cancer and frequency of genotypes of the CASP7 gene.
| Genotype/Haplotype | Crude OR |
| Statistical power | Prior probability | ||||
| 0.25 | 0.1 | 0.01 | 0.001 | 0.0001 | ||||
|
| ||||||||
| TT vs. CC/CT | 0.82 (0.69–0.97) | 0.023 | 0.997 | 0.065 |
| 0.696 | 0.958 | 0.996 |
| TT vs. CC/CT | ||||||||
| ≤59 | 0.77 (0.60–0.98) | 0.035 | 0.863 | 0.109 | 0.267 | 0.801 | 0.976 | 0.998 |
| Never smoker | 0.77 (0.61–0.91) | 0.026 | 0.873 | 0.082 | 0.211 | 0.747 | 0.967 | 0.997 |
| Never drinker | 0.80 (0.65–0.98) | 0.028 | 0.954 | 0.081 | 0.209 | 0.744 | 0.967 | 0.997 |
| Non-cardia | 0.80 (0.66–0.96) | 0.019 | 0.964 | 0.056 |
| 0.661 | 0.952 | 0.995 |
| Combined | ||||||||
| 1–2 vs. 0 | 0.82 (0.68–0.99) | 0.042 | 0.998 | 0.112 | 0.275 | 0.806 | 0.977 | 0.998 |
| 3–4 vs. 0 | 0.87 (0.75–1.00) | 0.046 | 0.976 | 0.417 | 0.682 | 0.959 | 0.996 | 1.000 |
| ≥1 vs. 0 | ||||||||
| ≤59 | 0.75 (0.59–0.95) | 0.019 | 0.807 | 0.066 |
| 0.700 | 0.959 | 0.996 |
| Female | 0.72 (0.53–0.99) | 0.040 | 0.671 | 0.152 | 0.349 | 0.855 | 0.983 | 0.998 |
| Never smoker | 0.76 (0.60–0.96) | 0.019 | 0.848 | 0.063 |
| 0.689 | 0.957 | 0.996 |
| Never drinker | 0.78 (0.64–0.96) | 0.016 | 0.931 | 0.049 |
| 0.630 | 0.945 | 0.994 |
| Non-cardia | 0.78 (0.65–0.94) | 0.010 | 0.943 | 0.031 |
| 0.512 | 0.914 | 0.991 |
The crude OR reported in Table 2.
The chi-square test of the genotype distributions reported in Table 2.
Statistical power was calculated using the number of observations in the study and the OR and P values in this table.
Figure 2mRNA expression level of the CASP7 gene in EBV-transformed lymphoblastoid cell lines.
(A) mRNA expression in 261 HapMap cell lines of all population. (B) mRNA expression in 82 HapMap cell lines of unrelated Asian. (C) mRNA expression in 45 HapMap cell lines of unrelated CHB.